GT Biopharma, Inc.
GTBP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.03 | 0.02 | -0.01 |
| FCF Yield | -159.09% | -30.37% | -43.68% | -42.66% |
| EV / EBITDA | 0.06 | -3.10 | -1.39 | -0.49 |
| Quality | ||||
| ROIC | -280.20% | -31.41% | 197.14% | 225.33% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.18 | 2.10 | 2.84 | 0.65 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -22.00% | -36.88% | 10.78% | 9.83% |
| Safety | ||||
| Net Debt / EBITDA | 0.75 | 3.46 | 1.22 | 1.05 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |